A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)

  title={A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)
  author={Carol J. Gallione and Gabriela M. Repetto and Eric Legius and Anil K. Rustgi and Susan Schelley and Sabine Tejpar and Grant Mitchell and {\'E}ric Drouin and Cornelius J. J. Westermann and Douglas A. Marchuk},
  journal={The Lancet},

Tables from this paper

Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation

Patients with HHT and SMAD4 mutations are at significant risk of JP and CRC and it is essential for HHT patients to undergo genetic testing to determine if they have SMad4 mutations so that appropriate gastrointestinal screening and surveillance forJP and CRC can be completed.

Mutation analysis in hereditary haemorrhagic telangiectasia in Germany reveals 11 novel ENG and 12 novel ACVRL1/ALK1 mutations

An analysis of the genotype–phenotype correlation is consistent with a more common frequency of pulmonary arteriovenous malformations in patients with ENG mutations than in Patients with ACVRL1 mutations in the collective.

A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5

It is concluded that classical HHT with pulmonary involvement can result from mutations in an unidentified gene on chromosome 5, which should further illuminate HHT pathogenic mechanisms in which aberrant transforming growth factor (TGF)-β signalling is implicated.

The prevalence of hereditary hemorrhagic telangiectasia in Juvenile Polyposis syndrome patients with SMAD4 mutations

The aim was to determine the prevalence of HHT in patients with JPS with a SMAD4 mutation including those who underwent systematic screening for AVM’s and families carrying a germline SMad4 mutation.

SMAD4 mutation and the combined syndrome of juvenile polyposis syndrome and hereditary haemorrhagic telangiectasia

Patients with JPS due to a SMAD4 mutation should be screened for the vascular lesions associated with HHT, especially occult AVMs in visceral organs, which may potentially present catastrophically with serious medical consequences.

Clinical Features and Mutations in the ENG, ACVRL1, and SMAD4 genes in Korean Patients with Hereditary Hemorrhagic Telangiectasia

The genetic and allelic heterogeneity underlying HHT is shown to show significant phenotypic variability and genetic heterogeneity with wide ethnic and geographic variations in Korean patients with HHT.

National mutation study among Danish patients with hereditary haemorrhagic telangiectasia

On the genetic heterogeneity in the Danish national HHT population, the adding of an extra criterion to the Curaçao criteria is suggested and when to assign pathogenicity to missense and splice site mutations is discussed.

Mutational and clinical spectrum of Japanese patients with hereditary hemorrhagic telangiectasia

This study reports the largest series of mutational and clinical analyses for East Asians with 281 Japanese HHT patients from 150 families, and identifies 80 pathogenic/likely pathogenic variants in the ENG and ACVRL1 genes.

Juvenile polyposis syndrome and hereditary haemorrhagic telangiectasia caused by the SMAD4 gene mutation in a paediatric patient – a case report and a review of the literature

A case of a teenage boy with an affected family history, who was admitted to the department in order to broaden the diagnosis of the causes of his rectal bleeding and recurrent nasal bleeding, and polyps in his gastrointestinal tract and arteriovenous malformations in his lungs were revealed.



Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations

Evidence is provided that the HHT phenotype caused by mutations in endoglin (HHT1) is distinct from, and more severe than, HHT caused by mutation in ALK1 (H HT2), which has significant implications for diagnosis, screening, and treatment in the two different forms of HHT.

SMAD genes in juvenile polyposis

It is confirmed that SMAD4 is a gene predisposing to JP and the existence of further JP loci other than the SMAD2, SMAD3, or SMAD7 genes is suggested.

Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis

Findings indicate involvement of an additional gene in the transforming growth factor-β (TGF-β) superfamily in the genesis of JP, and document an unanticipated function for BMP in colonic epithelial growth control.

Hereditary hemorrhagic telangiectasia with juvenile polyposis--coincidence or linked autosomal dominant inheritance?

The coexistence of both diseases in a girl and her father in addition to twelve members of five families and two sporadic cases reported in the literature implies a new phenotype which may be important in elucidating the underlying genetics in HHT and FJP.

Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2

A new 4 cM interval for ORW2 is reported that does not overlap with any previously defined and suggests a critical role for ALK1 in the control of blood vessel development or repair.

A survey of phenotypic features in juvenile polyposis.

It is sought to determine whether there are consistent extracolonic phenotypic abnormalities in JP patients and how frequently this would allow diagnosis of one of the genetic syndromes known to be associated with juvenile polyposis.

Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

A diagnosis of HHT cannot be established in patients with only two criteria, but should be recorded as possible or suspected to maintain a high index of clinical suspicion and to be considered at risk in view of age-related penetration in this disorder.

Mutations in the SMAD4/DPC4 gene in juvenile polyposis.

It is shown that a subset of juvenile polyposis families carry germ line mutations in the gene SMAD4 (also known as DPC4), located on chromosome 18q21.1, that encodes a critical cytoplasmic mediator in the transforming growth factor-beta signaling pathway.

Juvenile polyposis occurring in hereditary hemorrhagic telangiectasia.

Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century

This review focuses on the evolving evidence base for HHT management, issues regarding pregnancy and prothrombotic treatments, and discusses the molecular and cellular changes that underlie this disease.